CannaPharmaRX’s latest 10-Q filing details progress in ramping up its cannabis production capacity, with six of ten growing rooms currently active at its Alberta facility. The company is strategically prioritizing expansion into European markets by pursuing EU-GMP certification that would enable direct shipment within the European Union, reducing costs and delivery times. Despite these operational moves, financial strains remain acute, highlighted by severe working capital deficiencies and large outstanding debt obligations managed through creditor negotiations.